Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous 5-fluorouracil Infusion Plus Long Acting Octreotide in Advanced Well Differentiated Neuroendocrine Carcinomas
NCT00953394Phase 2Completed
- Sponsor
- University of Turin
- Start
- Feb 2002
- Primary completion
- Feb 2006
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, Octreotide long-acting injection in neuroendocrine carcinoma (NEC), sponsored by University of Turin. Started Feb 2002; status: completed.
02
Drugs
fluorouracilOctreotide long-acting injection
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT00953394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00953394.